Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI takes the guesswork out of insulin dosing for hospital patients

NCT ID NCT06319300

Disease control Sponsor: Shanghai Zhongshan Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether an artificial intelligence system can safely and effectively adjust insulin doses for people with type 2 diabetes while they are in the hospital. About 144 participants will be randomly assigned to have their insulin doses set either by the AI system or by their doctors. The goal is to see if the AI helps keep blood sugar in a healthy range more consistently.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Artificial intelligence-assisted insulin dose adjustment system
What this could lead to
If successful, this AI system could help doctors manage blood sugar more effectively in hospitalized patients, reducing complications.
What could go wrong
This is a relatively small, early-stage study. The AI may not outperform standard care in all patients, and technical issues could arise.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

144 people

The number who actually took part.

Started

Apr 2024

Finished

Sep 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of type 2 diabetes mellitus \> 3 months * Age≥18 years old * Receiving glucose-lowering management for at least 90 days * Blood glucose:7.8-22.2 mmol/L * Length of proposed hospitalisation ≥5 days. Exclusion Criteria: * Type 1 diabetes mellitus, other special types of diabetes mellitus * BG\>22.2 mmol/L, or acute complications of diabetes, such as diabetic ketoacidosis, diabetic hyperosmolar state * History of severe or repeated hypoglycaemia * BMI≥45 kg/m2 * Pregnant and lactating women * Clinically relevant liver disease (established cirrhosis and portal hypertension) * Presence of severe renal disease (serum creatinine ≥3.0 mg/dL or estimated glomerular filtration rate \<30 ml/min/1.73 m2) * Severe cardiac insufficiency * Patients undergoing corticosteroid therapy (equivalent to a prednisone dose \>5 mg/day) * Psychiatric abnormalities or impaired cognitive function * Patients with severe oedema, infection, or peripheral blood circulation disorder * Patients with severe illness or patients to be transferred to ICU for treatment * Surgery of the heart or abdomen that may have a significant impact on the test is planned during hospitalisation * Expected to be NPO for an extended period * Any medical or psychological conditions, or medications that, in the doctor's judgment, could interfere with the results * Subjects who cannot comply with the protocol.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetes type 2 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diabetes mellitus Insulin Resistance type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetes type 2

Contacts and locations

Locations

  • Zhongshan Hospital, Fudan University

    Shanghai, Shanghai Municipality, 200032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.